• Skip to primary navigation
  • Skip to main content
  • Skip to footer

LKT Labs

Biochemicals for Life Science Research

  • Products
    • New Products
    • Cancer Biology
    • Cardiovascular
    • Endocrine Signaling and Immunology
    • Metabolic and GI Pathology
    • Microbiology
    • Natural Products
    • Neuroscience
    • Peptides
    • Pharmaceutical Impurities and Derivatives
    • Stem Cell Modulators
  • Services
    • Custom Synthesis
    • Natural Product Isolation
    • Analytical Services
  • Int’l Distributors
  • Support
    • About LKT Labs
    • General Inquiry
    • Bulk Quote Request
    • Document Request
    • Technical Support
    • Catalog Request
    • Product Flyers
  • Contact Us
  • Cart
  • Login / Register
BYL719

BYL719

Product ID B9700
Cas No. 1217486-61-7
Purity ≥99%, ≥99%ee
Product Unit SizeCostQuantityStock
1 mg $63.00 In stock
5 mg $116.00 In stock
25 mg $173.00 In stock
100 mg $446.00 In stock
Bulk Quote

Quicklinks

  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Description
  • Product Info
  • Shipping and Storage
  • Downloads
  • References
  • Custom Order

Description

BYL-719 is an ATP-competitive oral PI3K inhibitor selective for the p110α isoform that is activated by a mutant PIK3CA gene in HER2+ breast cancers and gastric cancers. BYL-719 exhibits anticancer chemotherapeutic activity and inhibits proliferation in a variety of cell lines. IGF1 and neuregulin 1 activate mTOR, a downstream target of PI3K that mediates resistance to BYL-719 in some in vitro cancer models. This compound also decreases invasion and epithelial-to-mesenchymal transition (EMT) in cellular and animal models of squamous cell lung cancer.

Product Info

Cas No.

1217486-61-7

Purity

≥99%, ≥99%ee

Formula

C19H22F3N5O2S

Formula Wt.

441.47

Chemical Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

IUPAC Name

(2S)-1-N-[4-methyl-5-[2-(1,1, 1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1, 3-thiazol-2-yl]pyrrolidine-1,2-dicarboxamide

Synonym

Alpelisib, NVP-BYL719, BYL-719

Solubility

DMSO 88 mg/mL (199.33 mM) Ethanol 2 mg/mL (4.53 mM) Water Insoluble

Appearance

White Crystal Powder

Shipping and Storage

Store Temp

-20°C

Ship Temp

Ambient

Downloads

MSDS

B9700 MSDS PDF

Info Sheet

B9700 Info Sheet PDF

References

Bonelli MA, Cavazzoni A, Saccani F, et al. Inhibition of PI3K pathway reduces invasiveness and epithelial-to-mesenchymal transition in squamous lung cancer cell lines harboring PIK3CA gene alterations. Mol Cancer Ther. 2015 May 26. [Epub ahead of print]. PMID: 26013318.

Elkabets M, Vora S, Juric D, et al. mTORC1 Inhibition Is Required for Sensitivity to PI3K p110α Inhibitors in PIK3CA-Mutant Breast Cancer. Sci Transl Med. 2013 Jul 31;5(196):196ra99. PMID: 23903756.

Abstract: Juric. BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. American Association for Cancer Research. 2012.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • V1810

    Vecuronium Bromide

    Non-depolarizing NMJ blocker; nAChR antagonist....

    ≥98%
  • U698576

    Urolithin B

    Ellagic acid derivative produced by gut microfl...

    ≥99%
  • E0001

    E64

    Cysteine protease inhibitor.

    ≥99%
  • D3322

    Diflunisal

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • M5794

    Moxifloxacin Hydrochloride

    Fluoroquinolone; topoisomerase IV, topoisomeras...

    ≥98%
  • T7133

    Trimetazidine Dihydrochloride

    Long-chain 3-ketoacyl-CoA thiolase inhibitor, p...

    ≥99%
  • G6817

    Green Tea Polyphenols

    Extract containing catechins and flavonoids fou...

    ≥98%
  • P5885

    Povidone Iodine

    Polyvinyl pyrrolidone polymer, disinfectant.

    ≥98%
  • T1652

    Teniposide

    Podophyllotoxin derivative; topoisomerase II in...

    ≥97%
  • G062680

    GBR-12909 Dihydrochloride

    Dopamine reuptake inhibitor (DRI).

    ≥98%
  • N0062

    D,L-Naproxen

    NSAID; COX-1/2 inhibitor.

    ≥98%
  • B030964

    BAY-1816032

    BUB1 inhibitor.

    ≥99%
  • E5221

    Endothelin-2, human

    Endogenous peptide involved in vascular contrac...

    ≥95%
  • Z0222

    Zafirlukast

    VEGF-C/Nrp2 inhibitor. Leukotriene receptor ant...

    ≥98%
  • D019601

    Dapagliflozin

    SGLT2 inhibitor

    ≥98%
  • S5869

    Sorafenib Tosylate

    c-Raf, RET, VEGFR1 inhibitor, potential HMT inh...

    ≥99%
  • A2046

    Aflatoxin B2

    Mycotoxin produced by species of Aspergillus; D...

    ≥98%
  • V3276

    Vitamin E, Natural

    Antioxidant.

    ≥97%
  • T4800

    TM3-0089 Sodium Monohydrate

    CRTH2 inhibitor.

    ≥98%
  • C1635

    Ceftazidime Hydrate

    β-lactam cephalosporin; penicillin binding pro...

    ≥97%

Footer

  • Contact Us
  • About Us
  • Site Map
  • Terms and Conditions
LKT Laboratories, Inc.
545 Phalen Blvd.
St. Paul MN, 55130

Ph: (888)-558-5227
Fax: (888)-558-7329

©2026 LKT Laboratories, All Rights Reserved - Products for research use only